SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0001493152-23-033652
Filing Date
2023-09-26
Accepted
2023-09-25 18:46:08
Documents
5

Document Format Files

Seq Description Document Type Size
1 formsc13d.htm SC 13D 156396
2 ex24-1.htm EX-24.1 11991
3 ex24-2.htm EX-24.2 11727
4 ex24-3.htm EX-24.3 12377
5 ex99-1.htm EX-99.1 9793
  Complete submission text file 0001493152-23-033652.txt   203676
Mailing Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121 858-794-9600
Calidi Biotherapeutics, Inc. (Subject) CIK: 0001855485 (see all company filings)

IRS No.: 862967193 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-92875 | Film No.: 231276888
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 4475 EXECUTIVE DRIVE, SUITE 200 SAN DIEGO CA 92121
Business Address
Camaisa Allan (Filed by) CIK: 0001990674 (see all company filings)

Type: SC 13D